Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines
| Autor: | C.M.J. Potting, Abhishek Kandwal, M. Elvira P. Correa, Tanya Rouleau, Charles L. Loprinzi, Vinisha Ranna, Karis Kin Fong Cheng, Paolo Bossi, Karen Chiang, Anusha Vaddi, Juan J. Toro, Douglas E. Peterson, Sharon Elad, Takehiko Mori, Rajesh V. Lalla |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Mucositis Melphalan medicine.medical_specialty medicine.medical_treatment Antineoplastic Agents Cryotherapy Guidelines Medical Oncology Oral mucositis 03 medical and health sciences 0302 clinical medicine Bolus (medicine) Neoplasms medicine Humans 030212 general & internal medicine Intensive care medicine Cancer Stomatitis Chemotherapy business.industry Evidence-based medicine Guideline medicine.disease Triage Oncology 030220 oncology & carcinogenesis business medicine.drug |
| Zdroj: | Supportive Care in Cancer. 28:2449-2456 |
| ISSN: | 1433-7339 0941-4355 |
| DOI: | 10.1007/s00520-019-05217-x |
| Popis: | To update the 2013 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) clinical practice guidelines on oral cryotherapy for the management of oral mucositis (OM) caused by cancer therapies. A systematic review was conducted by the Mucositis Study Group of MASCC/ISOO. The evidence for each intervention for specific cancer treatment modalities was assigned a level of evidence (LoE). The findings were added to the database used to develop the 2013 MASCC/ISOO clinical practice guidelines. Based on the LoE, the guidelines were set as: recommendation, suggestion, or no guideline possible. A total of 114 papers were identified: 44 from PubMed and 70 from Web of Science. After abstract triage and merging with the 2013 database, 36 papers were reviewed. The LoE for prevention of OM with oral cryotherapy in patients undergoing autologous hematopoietic stem cell transplant using high-dose melphalan conditioning protocols was upgraded, and the guideline changed to recommendation. Additionally, the recommendation for prevention of OM with oral cryotherapy in patients receiving bolus 5-fluorouracil for the treatment of solid tumors was confirmed. No guidelines were possible for other clinical settings. The evidence supports recommendations for the use of oral cryotherapy for the prevention of OM for either (i) patients undergoing autologous hematopoietic stem cell transplant with high-dose melphalan conditioning protocols or (ii) patients receiving bolus 5-fluorouracil chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink